Accentia Biopharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Accentia Biopharmaceuticals, Inc.
After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
Tricky drug development challenges have held back the NLRP3 inhibitor field for decades but Ventus and its many rivals believe the class can deliver on its huge potential, from Parkinson’s disease to NASH and arthritis.
An awaited update on early data for a CAR-NK therapeutic shows disappointing efficacy and duration, but a different chemotherapy conditioning regimen for lymphodepletion is showing early promise in acute myeloid leukemia.
- Medical Devices
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Biovest International, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.